Your browser doesn't support javascript.
loading
A double-blind, double-dummy, randomized controlled, multicenter trial of 99Tc-methylene diphosphonate in patients with moderate to severe rheumatoid arthritis.
Fu, Qiong; Feng, Ping; Sun, Ling-Yun; Zuo, Xiao-Xia; Zhao, Dong-Bao; He, Dong-Yi; Wu, Hua-Xiang; Zhang, Wei; Zhang, Wei; Du, Fang; Bao, Chun-De.
Afiliación
  • Fu Q; Department of Rheumatology, Renji Hospital of Shanghai Jiaotong University School of Medicine, Shanghai 200000, China.
  • Feng P; National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, Institute of Clinical Trials, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
  • Sun LY; Department of Rheumatology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu 210008, China.
  • Zuo XX; Department of Rheumatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
  • Zhao DB; Department of Rheumatology and Immunology, Changhai Hospital, Shanghai 200433, China.
  • He DY; Department of Rheumatology, Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai 200052, China.
  • Wu HX; Department of Rheumatology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China.
  • Zhang W; Department of Rheumatology, Renji Hospital of Shanghai Jiaotong University School of Medicine, Shanghai 200000, China.
  • Zhang W; Department of Quality Control, Cheng Fei Hospital, Chengdu, Sichuan 610091, China.
  • Du F; Department of Rheumatology, Renji Hospital of Shanghai Jiaotong University School of Medicine, Shanghai 200000, China.
  • Bao CD; Department of Rheumatology, Renji Hospital of Shanghai Jiaotong University School of Medicine, Shanghai 200000, China.
Chin Med J (Engl) ; 134(12): 1457-1464, 2021 May 19.
Article en En | MEDLINE | ID: mdl-34039871
ABSTRACT

BACKGROUND:

Clinical observational studies revealed that 99Tc-methylene diphosphonate (99Tc-MDP) could reduce joint pain and swollenness in rheumatoid arthritis (RA) patients. This multicenter, randomized, double-blind, double-dummy study aimed to evaluate the effects of 99Tc-MDP plus methotrexate (MTX) vs. MTX alone or 99Tc-MDP alone on disease activity and structural damage in MTX-naïve Chinese patients with moderate to severe RA.

METHODS:

Eligible patients with moderate to severely active RA were randomized to receive 99Tc-MDP plus MTX (n = 59) vs. MTX (n = 59) alone or 99Tc-MDP (n = 59) alone for 48 weeks from six study sites across four provinces in China. The primary outcomes were the American College of Rheumatology 20% improvement (ACR20) response rates at week 24 and changes in modified total Sharp score at week 48.

RESULTS:

At week 24, the proportion of participants achieving ACR20 was significantly higher in the MTX + 99Tc-MDP combination group (69.5%) than that in the MTX group (50.8%) or 99Tc-MDP group (47.5%) (P = 0.03 for MTX + 99Tc-MDP vs. MTX, and MTX + 99Tc-MDP vs.99Tc-MDP, respectively). The participants in the MTX + 99Tc-MDP group and the 99Tc-MDP group had significantly less important radiographic progression than the participants in the MTX group over the 48 weeks (MTX + 99Tc-MDP vs. MTX P = 0.03, 99Tc-MDP vs. MTX P = 0.03, respectively). There was no significant difference in terms of adverse events (AEs) among the groups. No serious AEs were observed.

CONCLUSIONS:

This study demonstrated that the combination of 99Tc-MDP with MTX inhibited structural damage and improved disease activity in RA patients compared with MTX and 99Tc-MDP monotherapies, without increasing the rate of AEs. Additional clinical studies of 99Tc-MDP therapy in patients with RA are warranted. TRIAL REGISTRATION Chictr.org, ChiCTR-IPR-14005684; http//www.chictr.org.cn/showproj.aspx?proj=10088.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 Problema de salud: 1_doencas_nao_transmissiveis Asunto principal: Artritis Reumatoide / Antirreumáticos Tipo de estudio: Clinical_trials / Observational_studies Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Chin Med J (Engl) Año: 2021 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 Problema de salud: 1_doencas_nao_transmissiveis Asunto principal: Artritis Reumatoide / Antirreumáticos Tipo de estudio: Clinical_trials / Observational_studies Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Chin Med J (Engl) Año: 2021 Tipo del documento: Article País de afiliación: China
...